Bridge City Capital LLC Sells 2,019 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Bridge City Capital LLC reduced its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 0.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 229,196 shares of the company’s stock after selling 2,019 shares during the quarter. Bridge City Capital LLC owned 0.50% of Pacira BioSciences worth $4,318,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Caitlin John LLC lifted its holdings in shares of Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after acquiring an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after purchasing an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after purchasing an additional 513 shares during the last quarter. Virtus Investment Advisers Inc. acquired a new stake in Pacira BioSciences in the third quarter valued at approximately $98,000. Finally, Quest Partners LLC grew its stake in shares of Pacira BioSciences by 137.6% during the third quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock worth $142,000 after buying an additional 5,449 shares during the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Trading Up 1.3 %

NASDAQ:PCRX opened at $24.14 on Friday. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm’s fifty day moving average is $24.44 and its 200-day moving average is $19.58. The firm has a market cap of $1.12 billion, a P/E ratio of -11.89 and a beta of 0.86.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on PCRX shares. Barclays raised their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, February 28th. HC Wainwright lifted their price target on Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price objective for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. Finally, Needham & Company LLC boosted their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $27.22.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.